son-1010
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 20, 2022 (NCT05352750)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05756907 | Phase 1/Phase 2 (Phase 2) | Sep 15, 2023 | Roche, Sonnet BioTherapeutics |
| NCT05408572 | Early Phase 1 (Phase 1) | Jul 27, 2022 | Sonnet BioTherapeutics |
| NCT05352750 | Phase 1 | Apr 20, 2022 | Sonnet BioTherapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sonnet BioTherapeutics | For profit | 3 | 3 | 2 | 2022 |
| Roche | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1